Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy”

Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

ZVRA has been the topic of several other research reports. Guggenheim started coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Trading Up 2.0 %

Shares of ZVRA stock opened at $8.02 on Wednesday. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The stock has a market capitalization of $428.08 million, a P/E ratio of -4.07 and a beta of 2.01. The firm’s 50 day moving average is $8.56 and its 200 day moving average is $7.92.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the business earned ($0.40) earnings per share. Research analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Management LLC raised its holdings in Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after acquiring an additional 1,717 shares during the period. City State Bank grew its position in shares of Zevra Therapeutics by 14.1% during the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after purchasing an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the period. International Assets Investment Management LLC lifted its holdings in Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. Finally, IFG Advisors LLC boosted its stake in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after purchasing an additional 7,700 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.